Tamoxifen downregulates TGF-β production in keloid fibroblasts

Annals of Plastic Surgery

Volumn 40, Issue 5, 1998, Pages 490-493

  Chau, Dorothy ^a   Mancoll, John S ^b   Lee, Steve ^a   Zhao, Jiangang ^b   Phillips, Linda G ^b   Gittes, George K ^b   Longaker, Michael T ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG MECHANISM; FIBROBLAST; KELOID; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY MECHANISM;

CELL CULTURE TECHNIQUES; DOWN-REGULATION; ESTROGEN ANTAGONISTS; FIBROBLASTS; HUMANS; KELOID; LUCIFERASES; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031925970     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000637-199805000-00008     Document Type: Article

References (21)

1. McCauley RL, Chopra V, et al. Altered cytokine production in black patients with keloids. J Clin Immunol 1992;12:300-308
2. Di Cesare PE, Cheung DT, Perelman N, et al. Alteration of collagen composition and crosslinking in keloid tissues. Matrix 1990;10:172-178
3. Kischer CW. The microvessels in hypertrophic scars, keloids, and related lesions: a review. J Submicrosc Cytol Pathol 1992;2:281-296
4. Martin P. Wound healing - aiming for perfect skin regeneration. Science 1997;276:75-81
5. Datubo-Brown DD. Keloids: a review of the literature. Br J Plast Surg 1990;43:70-77
6. Dickens TA, Collett AA. The pharmacological manipulation of members of the transforming growth factor beta family in the chemoprevention of breast cancer. Bioessays 1993;15:71-74
7. Murphy L. Antiestrogen action and growth factor regulation. Breast Cancer Res Treat 1994;31:61-71
8. Noguch S, Motomura K, Inaji H, et al. Down regulation of transforming growth factor alpha by tamoxifen in human breast cancer. Cancer 1993;72:131-136
9. Jordan VC. Growth factor regulation by tamoxifen is demonstrated in patients with breast cancer. Cancer 1993;72:1-2
10. Owens LV, Cance WG, Huth JF. Rstroperitoneal fibrosis treated with tamoxifen. Am Surg 1995;61:842-844
11. Timmons MJ. Fibromatosis, desmoids, fibroblasts, and tamoxifen. Br J Plast Surg 1994;47:378-380
12. Mancoll JS, Zhao J, McCauley RL, et al. The inhibitory effect of tamoxifen on keloid fibroblasts. Surg Forum 1996;47:718-720
13. Abe M, Harpel JG, Metz CN, et al. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994;216:276-284
14. Mignatti P, Rifken DB, Welgus HG, et al. In: Clark RAF, ed. Proteinases and tissue remodeling. The molecular and cellular biology of wound repair. 2nd ed. New York: Plenum Press, 1996:427-474
15. Sung JJ, Friedman DW, Harpel J, et al. Elevated endogenous TGF-β production in keloid and hypertrophic scar fibroblast cultures. Presented at the Plastic Surgery Research Council, 41st Annual Meeting; St. Louis, MO; June 1996
16. Peltonen J, Hsiao LL, Jaakkola S, et al. Activation of collagen gene expression in keloids: co-localization of type I and VI collagen and transforming growth factor-β1 mRNA. J Invest Dermatol 1991;92:240-248
17. Ashcroft GS, Dodsworth EVB, Tarnuzzer RW, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-β1 levels. Nat Med 1997;3:1209-1215
18. Shah M, Foreman DM, Ferguson MWJ. Neutralising antibody to TGF-β1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 1994;107:1137-1157
19. Shah M, Foreman DM, Ferguson MW. Control of scarring in adult wounds by neutralising antibody to transforming growth factor β. Lancet 1992;339:213-214
20. Nakajima H, Kishi T, Tsuchiya H, et al. Exposure of fibroblasts derived from keloid patients to low-energy electromagnetic fields: preferential inhibition of cell proliferation, collagen synthesis, and transforming growth factor beta expression in keloid fibroblasts in vitro. Ann Plast Surg 1997;39:536-541
21. Glasberg SB, Rofeim O, Canick ML. Early results of a trial of calcium antagonists to treat and prevent keloids and hypertrophie scars. Presented at the annual meeting of the Northeastern Society of Plastic Surgeons, Bermuda, October 1997